Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized clinical trial comparing high versus standard dose of ribavirin plus peginterferon alfa-2a in hepatitis C genotype 3 and high viral load. Dargen-3 study.
Fernández-Rodríguez CM, Morillas RM, Masnou H, Navarro JM, Bárcena R, González JM, Martín-Martín L, Poyato A, Miquel-Planas M, Jorquera F, Casanovas T, Salmerón J, Calleja JL, Solà R, Alonso S, Planas R, Romero-Gomez M. Fernández-Rodríguez CM, et al. Among authors: barcena r. Gastroenterol Hepatol. 2014 Jan;37(1):1-8. doi: 10.1016/j.gastrohep.2013.10.005. Epub 2013 Dec 17. Gastroenterol Hepatol. 2014. PMID: 24360571 Clinical Trial.
Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR). Fernández-Rodríguez CM, et al. Among authors: barcena r. Am J Gastroenterol. 2010 Oct;105(10):2164-72; quiz 2173. doi: 10.1038/ajg.2010.294. Epub 2010 Aug 10. Am J Gastroenterol. 2010. PMID: 20700116
Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X; Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis. Calleja JL, et al. Among authors: barcena r. Liver Int. 2015 Jan;35(1):90-100. doi: 10.1111/liv.12656. Epub 2014 Sep 15. Liver Int. 2015. PMID: 25113158 Clinical Trial.
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
Diago M, Crespo J, Olveira A, Pérez R, Bárcena R, Sánchez-Tapias JM, Muñoz-Sánchez M, Romero-Gómez M. Diago M, et al. Among authors: barcena r. Aliment Pharmacol Ther. 2007 Oct 15;26(8):1131-8. doi: 10.1111/j.1365-2036.2007.03470.x. Aliment Pharmacol Ther. 2007. PMID: 17894655 Free article. Clinical Trial.
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.
Sánchez-Tapias JM, Diago M, Escartín P, Enríquez J, Romero-Gómez M, Bárcena R, Crespo J, Andrade R, Martínez-Bauer E, Pérez R, Testillano M, Planas R, Solá R, García-Bengoechea M, Garcia-Samaniego J, Muñoz-Sánchez M, Moreno-Otero R; TeraViC-4 Study Group. Sánchez-Tapias JM, et al. Among authors: barcena r. Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016. Gastroenterology. 2006. PMID: 16890599 Clinical Trial.
Acute hepatitis C in Spain: a retrospective study of 131 cases.
Pérez-Álvarez R, García-Samaniego J, Solá R, Pérez-López R, Bárcena R, Planas R, Cañete N, Manzano ML, Gutiérrez ML, Morano L, Rodrigo L. Pérez-Álvarez R, et al. Among authors: barcena r. Rev Esp Enferm Dig. 2012 Feb;104(1):21-8. doi: 10.4321/s1130-01082012000100005. Rev Esp Enferm Dig. 2012. PMID: 22300113 English, Spanish.
[Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Crespo J, Berenguer M, Pérez F, Fernández I, González O, Bárcena R, Buti M, López J, Calleja JL; en representación del grupo de investigadores del estudio LEAD-IN. Crespo J, et al. Among authors: barcena r. Gastroenterol Hepatol. 2015 Nov;38(9):517-24. doi: 10.1016/j.gastrohep.2015.04.002. Epub 2015 May 12. Gastroenterol Hepatol. 2015. PMID: 25976446 Spanish.
Cost-Effectiveness Analysis Of Triple Therapy With Peginterferon, Ribavirin, And Boceprevir For The Treatment Of Chronic Hepatitis C Virus Genotype 1 With Severe Fibrosis Under "Real-Life" Conditions.
Ruiz-Antorán B, Pascasio JM, Gea F, Barcena R, Larrubia J, Pérez ÁR, Sousa J, Romero GM, Solá R, de lR, Crespo J, Navarro J, Arenas J, Delgado M, Fernández RC, Planas R, Buti M, Forns X, Calleja JL. Ruiz-Antorán B, et al. Among authors: barcena r. Value Health. 2014 Nov;17(7):A367. doi: 10.1016/j.jval.2014.08.822. Epub 2014 Oct 26. Value Health. 2014. PMID: 27200769 Free article. No abstract available.
Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.
Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Oton E, et al. Among authors: barcena r. Am J Transplant. 2006 Oct;6(10):2348-55. doi: 10.1111/j.1600-6143.2006.01470.x. Epub 2006 Jul 26. Am J Transplant. 2006. PMID: 16869810 Free article.
144 results